tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Eliana Merle, 109 are a BUY (78.42%), 30 are a HOLD (21.58%).
Analyst Eliana Merle, currently employed at UBS, carries an average stock price target met ratio of 49.66% that have a potential upside of 51.38% achieved within 232 days.
Eliana Merle’s has documented 287 price targets and ratings displayed on 28 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on MRNA, Moderna at 22-Oct-2025.
Analyst best performing recommendations are on ZNTL (ZENTALIS PHARMACEUTICALS LLC).
The best stock recommendation documented was for ANAB (ANAPTYSBIO) at 11/7/2019. The price target of $28 was fulfilled within 1 day with a profit of $8.16 (22.57%) receiving and performance score of 225.66.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$45
$24.67 (121.35%)
$52
19 days ago
(02-Nov-2025)
20/28 (71.43%)
$23.53 (109.59%)
216
Hold
$19
$-1.33 (-6.54%)
$20
19 days ago
(02-Nov-2025)
6/12 (50%)
$-2.47 (-11.50%)
51
Buy
$45
$24.67 (121.35%)
$57
19 days ago
(02-Nov-2025)
3/23 (13.04%)
$23.53 (109.59%)
108
Buy
$45
$24.67 (121.35%)
$50
19 days ago
(02-Nov-2025)
5/7 (71.43%)
$23.53 (109.59%)
277
Buy
$32
$11.67 (57.40%)
$81
1 months 7 days ago
(14-Oct-2025)
12/13 (92.31%)
$6.77 (26.83%)
94
Which stock is Eliana Merle is most bullish on?
Which stock is Eliana Merle is most reserved on?
What Year was the first public recommendation made by Eliana Merle?
